Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

已完结 20 由羕发布于 2025/12/19 14:49:43

DOI:10.1182/blood.2025030113
作者：Luca Bertamini,Cathelijne Fokkema,Paula Rodriguez-Otero,Mark van Duin,Evangelos Terpos,Mattia D'Agostino,Vincent H J van der Velden,Niels W C J van de Donk,Michel Delforge,Christoph Driessen,Roman Haj
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving da

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierEffect of constant-current pulsed electric field thawing on proteins and water-holding capacity of frozen porcine longissimus muscle